Список литературы к Главe 2

74. Baliakas P., Hadzidimitriou A., Sutton L.A., Rossi D., Minga E., Villamor N. et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia // Leukemia. 2015. Vol. 29, N 2. P. 329–336.

75. Rossi D., Rasi S., Fabbri G., Spina V., Fangazio M., Forconi F. et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 2. P. 521–529.

76. Weissmann S., Roller A., Jeromin S., Hernandez M., Abaigar M., Hernandez­Rivas J.M. et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients // Leukemia. 2013. Vol. 27, N 12. P. 2393–2396.

77. Fabbri G., Khiabanian H., Holmes A.B., Wang J., Messina M., Mullighan C.G. et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome // J. Exp. Med. 2013. Vol. 210, N 11. P. 2273–2288.

78. Cortese D., Sutton L.A., Cahill N., Smedby K.E., Geisler C., Gunnarsson R. et al. On the way towards a «CLL prognostic index»: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population­based cohort // Leukemia. 2014. Vol. 28, N 3. P. 710–713.

79. Stilgenbauer S., Schnaiter A., Paschka P., Zenz T., Rossi M., Dohner K. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254.

80. Tausch E., Beck P., Schlenk R.F., Jebaraj B.J., Dolnik A., Yosifov D.Y. et al. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 // Haematologica. 2020. Vol. 105, N 10. P. 2440–2447.

81. Larrayoz M., Rose­Zerilli M.J., Kadalayil L., Parker H., Blakemore S., Forster J. et al. Non­coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial // Leukemia. 2017. Vol. 31, N 2. P. 510–514.

82. Jeromin S., Weissmann S., Haferlach C., Dicker F., Bayer K., Grossmann V. et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients // Leukemia. 2014. Vol. 28, N 1. P. 108–117.

83. Rossi D., Bruscaggin A., Spina V., Rasi S., Khiabanian H., Messina M. et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine­refractoriness // Blood. 2011. Vol. 118, N 26. P. 6904–6908.

84. Wang L., Brooks A.N., Fan J., Wan Y., Gambe R., Li S. et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia // Cancer Cell. 2016. Vol. 30, N 5. P. 750–763.

85. Te Raa G.D., Derks I.A., Navrkalova V., Skowronska A., Moerland P.D., van Laar J. et al. The impact of SF3B1 mutations in CLL on the DNA­damage response // Leukemia. 2015. Vol. 29, N 5. P. 1133–1142.

86. Navrkalova V., Young E., Baliakas P., Radova L., Sutton L.A., Plevova K. et al. ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres // Haematologica. 2016. Vol. 101, N 9. P. e369–e373.

87. Rossi D., Spina V., Bomben R., Rasi S., Dal­Bo M., Bruscaggin A. et al. Association between molecular lesions and specific B­cell receptor subsets in chronic lymphocytic leukemia // Blood. 2013. Vol. 121, N 24. P. 4902–4905.

88. Strefford J.C., Sutton L.A., Baliakas P., Agathangelidis A., Malcikova J., Plevova K. et al. Distinct patterns of novel gene mutations in poor­prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 // Leukemia. 2013. Vol. 27, N 11. P. 2196–2199.

89. Sutton L.A., Young E., Baliakas P., Hadzidimitriou A., Moysiadis T., Plevova K. et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B­cell receptors // Haematologica. 2016. Vol. 101, N 8. P. 959–967.

90. Oscier D.G., Rose­Zerilli M.J., Winkelmann N., Gonzalez de Castro D., Gomez B., Forster J. et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial // Blood. 2013. Vol. 121, N 3. P. 468–475.

91. Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S. et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild­type chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 12. P. 2854–2862.

92. Damm F., Mylonas E., Cosson A., Yoshida K., Della Valle V., Mouly E. et al. Acquired initiating mutations in early hematopoietic cells of CLL patients // Cancer Discov. 2014. Vol. 4, N 9. P. 1088–1101.

93. Young E., Noerenberg D., Mansouri L., Ljungstrom V., Frick M., Sutton L.A. et al. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia // Leukemia. 2017. Vol. 31, N 7. P. 1547–1554.

94. Mansouri L., Sutton L.A., Ljungstrom V., Bondza S., Arngarden L., Bhoi S. et al. Functional loss of IkappaBepsilon leads to NF­kappaB deregulation in aggressive chronic lymphocytic leukemia // J. Exp. Med. 2015. Vol. 212, N 6. P. 833–843.

95. Ljungstrom V., Cortese D., Young E., Pandzic T., Mansouri L., Plevova K. et al. Whole­exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations // Blood. 2016. Vol. 127, N 8. P. 1007–1016.

96. Bretones G., Alvarez M.G., Arango J.R., Rodriguez D., Nadeu F., Prado M.A. et al. Altered patterns of global protein synthesis and translational fidelity in RPS15­mutated chronic lymphocytic leukemia // Blood. 2018. Vol. 132, N 22. P. 2375–2388.

97. Ahn I.E., Underbayev C., Albitar A., Herman S.E., Tian X., Maric I. et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia // Blood. 2017. Vol. 129, N 11. P. 1469–1479.

98. Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M., Ruppert A.S. et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib // N. Engl. J. Med. 2014. Vol. 370, N 24. P. 2286–2294.

99. Woyach J.A., Ruppert A.S., Guinn D., Lehman A., Blachly J.S., Lozanski A. et al. BTK(C481S)­mediated resistance to ibrutinib in chronic lymphocytic leukemia // J. Clin. Oncol. 2017. Vol. 35, N 13. P. 1437–1443.

100. Scarfo L., Bonfiglio S., Sutton L.A., Ljungström V., Pandzic T., Cortese D. et al. BTK and PLCG2 mutations in patients with chronic lymphocytic leukemia relapsing on ibrutinib: a European Research Initiative on CLL (ERIC) study based on real­world evidence // Hemasphere. 2020. Vol. 4, N S161.

101. Burger J.A., Landau D.A., Taylor­Weiner A., Bozic I., Zhang H., Sarosiek K. et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition // Nat. Commun. 2016. Vol. 7. Article ID 11589.

102. Blombery P., Anderson M.A., Gong J.N., Thijssen R., Birkinshaw R.W., Thompson E.R. et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia // Cancer Discov. 2019. Vol. 9, N 3. P. 342–353.

103. Blombery P., Thompson E.R., Nguyen T., Birkinshaw R.W., Gong J.N., Chen X. et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax // Blood. 2020. Vol. 135, N 10. P. 773–777.

104. Sutton L.A., Ljungstrom V., Enjuanes A., Cortese D., Skaftason A., Tausch E. et al. Comparative analysis of targeted next­generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi­center study // Haematologica. 2021. Vol. 106, N 3. P. 682–691.

105. Landau D.A., Carter S.L., Getz G., Wu C.J. Clonal evolution in hematological malignancies and therapeutic implications // Leukemia. 2014. Vol. 28, N 1. P. 34–43.

106. Agathangelidis A., Ljungstrom V., Scarfo L., Fazi C., Gounari M., Pandzic T. et al. Highly similar genomic landscapes in monoclonal B­cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations // Haematologica. 2018. Vol. 103, N 5. P. 865–873.

107. Gruber M., Bozic I., Leshchiner I., Livitz D., Stevenson K., Rassenti L. et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia // Nature. 2019. Vol. 570, N 7762. P. 474–479.

108. Sutton L.A., Rosenquist R. The complex interplay between cell­intrinsic and cell­extrinsic factors driving the evolution of chronic lymphocytic leukemia // Semin. Cancer Biol. 2015. Vol. 34. P. 22–35.

109. Rossi D., Rasi S., Spina V., Bruscaggin A., Monti S., Ciardullo C. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia // Blood. 2013. Vol. 121, N 8. P. 1403–1412.

110. Rosenquist R., Ghia P., Hadzidimitriou A., Sutton L.A., Agathangelidis A., Baliakas P. et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations // Leukemia. 2017. Vol. 31, N 7. P. 1477–1481.

111. He J., Abdel­Wahab O., Nahas M.K., Wang K., Rampal R.K., Intlekofer A.M. et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting // Blood. 2016. Vol. 127, N 24. P. 3004–3014.

112. Wren D., Walker B.A., Bruggemann M., Catherwood M.A., Pott C., Stamatopoulos K. et al. Comprehensive translocation and clonality detection in lymphoproliferative disorders by next­generation sequencing // Haematologica. 2017. Vol. 102, N 2. P. e57–e60.